By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has entered into a comprehensive license agreement with U.S. biotech Accropeutics Bioscience. The deal grants Fosun exclusive rights to research, develop, manufacture, register, and market the AC‑201 molecule and any products containing AC‑201 as the active ingredient in Mainland China, Hong Kong SAR, and Macau SAR.
Deal Highlights
| Element | Details |
|---|---|
| Upfront Payment | RMB 60 million |
| Milestone Payments | Up to RMB 96 million contingent on regulatory and commercial milestones |
| Sales‑Based Payments | Tiered sales milestones and royalty payments tied to net sales within the licensed territories |
| Total Potential Value | RMB 156 million (up to) |
About AC‑201
- Structure – An orally administered, small‑molecule Janus Kinase (JAK) inhibitor engineered by Accropeutics Bioscience.
- Indication Focus – Primarily targeted at autoimmune disorders, with Phase 2 data in China demonstrating robust efficacy and safety in moderate‑to‑severe plaque psoriasis.
- Development Trajectory – The molecule is poised for further clinical development and potential registration in the Chinese market under Fosun’s umbrella.
Strategic Implications for Fosun
- Portfolio Diversification – Adds a high‑potential immunology asset to Fosun’s oncology‑centric pipeline.
- Market Opportunity – Autoimmune diseases are a rapidly growing therapeutic segment in China; AC‑201’s oral formulation and favorable safety profile could capture significant market share.
- Financial Upside – The tiered royalty structure aligns long‑term revenue with product performance, offering upside potential beyond the upfront and milestone payments.
Next Steps
Fosun will begin the regulatory registration process for AC‑201 in China immediately, with an expected filing window in Q1 2026. Accropeutics will collaborate on pre‑clinical and Phase 3 studies under Fosun’s manufacturing and commercial platform.-Fineline Info & Tech